摘要
目的从西罗莫司产生菌吸水链霉菌FC904发酵液的粗提物中分离纯化未知杂质FIM-R140,鉴定其化学结构。方法采用硅胶柱层析和制备液相分离纯化获得FIM-R140,进行理化性质以及IR、UV、NMR和HRMS等波谱分析,鉴定该杂质的化学结构。用SRB测定化合物体外抗肿瘤活性,用沙氏液体培养基二倍稀释法测定化合物的抗真菌活性。结果与结论纯化获得HPLC纯度为97.05%的FIM-R140,结构鉴定为31-差向雷帕霉素,为首次报道的西罗莫司同分异构体。FIM-R140的抗肿瘤活性较西罗莫司略低,对白念珠菌的抑菌作用弱于西罗莫司。
Objective To isolate and identify FIM-R140,a metabolite from the broth of the sirolimus producing strain Streptomyces hygroscopicus FC904.Methods FIM-R140 was separated and purified by silica gel chromatography and preparative liquid chromatography.Its chemical structure was determined by physicochemical properties and spectral analysis including IR,UV,NMR,and HRMS.The anti-cancer activity of FIM-R140 was determined by the SRB method in vitro,and the antifungal activity was evaluated by the serial two-fold broth dilution method.Results and Conclusion FIM-R140 with HPLC of 97.05%was obtained,and it was identified as 31-epi-rapamycin,a sirolimus isomer,which was reported for the first time.The anti-cancer activity and anti-fungus activity of FIM-R140 were slightly weaker than those of sirolimus.
作者
陈夏琴
陈晓明
刘颖
应加银
李夸良
黄捷
杨国新
Chen Xiaqin;Chen Xiaoming;Liu Ying;Ying Jiayin;Li Kuaiang;Huang Jie;Yang Guoxin(Fujian Institute of Microbiology,Fuzhou 350007)
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2024年第9期1013-1018,共6页
Chinese Journal of Antibiotics
基金
福建省公益类科研院所基本科研专项(No.2021R10050013)。